IP Library Granted Patent US 10,758,514
Granted Patent B2
US 10,758,514 · App. 15/969,422 · Granted Sep 1, 2020

Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour

Inventors: Wai Liu (London, GB); Katherine Scott (London, GB); Angus Dalgleish (London, GB); Marnie Duncan (Salisbury, GB); Colin Stott (Salisbury, GB)
Assignee: GW Pharma Limited
A61K31/352A61K31/05A61K36/185A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,514
App. No.
15/969,422
Granted
Sep 1, 2020
Kind
B2
Abstract

The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.

Claims (10)

1. A method for increasing radiosensitivity of glioma tumour cells, comprising:

administering a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD); and

administering radiation therapy,

wherein the combination of THC and CBD is administered prior to administering the radiation therapy, and the combination of THC and CBD administered increases radiosensitivity of the glioma tumour cells.

2. The method of claim 1 , wherein the combination of THC and CBD, and the radiation therapy are administered to a human having a glioma tumour.

3. The method of claim 1 , wherein the combination of THC and CBD, and the radiation therapy are administered to a human having glioblastoma multiforme (GBM).

4. The method of claim 1 , wherein one of the THC or CBD, or both in the combination are present in an extract obtained from a cannabis plant.

5. The method of claim 1 , wherein one of the THC or CBD, or both in the combination are in the form of a botanical drug substance.

6. The method of claim 1 , wherein one of the THC or CBD, or both in the combination are in an isolated or pure form.

7. The method of claim 1 , wherein the combination of THC and CBD is administered in a ratio of 1:1.

Assignments (4)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071103/0554 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
DEED OF ASSIGNMENT Recorded Jun 11, 2020
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 052914/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2020
From: LIU, WAI; SCOTT, KATHERINE; DALGLEISH, ANGUS; DUNCAN, MARNIE; STOTT, COLIN
To: GW PHARMA LIMITED
Reel/Frame 052885/0225 →